RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
Clinical trials for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to boost CAR-T cell staying power in lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether adding chidamide and a PD-1 inhibitor after CAR-T cell therapy can help prevent relapse in people with relapsed or refractory diffuse large B-cell lymphoma. The study plans to enroll 30 participants. The goal is to see if this maintenance strategy…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Armored cells take on tough lymphoma in early trial
Disease control Recruiting nowThis early study tests a new type of immune cell therapy called anti-PD1 armored CD19 CAR-T cells in 30 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. The cells are designed to better attack cancer and resist exhaustion. The main goal …
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
Phase: PHASE1 • Sponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC